Perfil psicosocial de un grupo de pacientes sobrevivientes de cáncer de mama

Resumen El propósito de este estudio fue evaluar las características psicosociales de un grupo de pacientes sobrevivientes de CaMa. Mediante un muestreo no probabilístico, por conveniencia, participaron diecisiete mujeres pertenecientes al Grupo de Sobrevivientes de Cáncer de Mama “Ave Fénix”, del CMN “20 de Noviembre”, ISSSTE. Se realizó una investigación no experimental, con diseño transversal exploratorio. Las pacientes respondieron el Cuestionario de Regulación Emocional, la Escala de Ansiedad y Depresión Hospitalaria y la Escala de Toronto de Alexitimia, durante una de las sesiones mensuales que sostiene el grupo. Los resultados sugieren que el grupo presenta un nivel alto de alexitimia, un nivel leve de ansiedad y poca depresión; además, utilizan la reevaluación cognitiva como estrategia regulación emocional. Estas características dan lugar a intervenciones psicosociales de grupo en su hospital.   Resumen El propósito de este estudio fue evaluar las características psicosociales de un grupo de pacientes sobrevivientes de CaMa. Mediante un muestreo no probabilístico, por conveniencia, participaron diecisiete mujeres pertenecientes al Grupo de Sobrevivientes de Cáncer de Mama “Ave Fénix”, del CMN “20 de Noviembre”, ISSSTE. Se realizó una investigación no experimental, con diseño transversal exploratorio. Las pacientes respondieron el Cuestionario de Regulación Emocional, la Escala de Ansiedad y Depresión Hospitalaria y la Escala de Toronto de Alexitimia, durante una de las sesiones mensuales que sostiene el grupo. Los resultados sugieren que el grupo presenta un nivel alto de alexitimia, un nivel leve de ansiedad y poca depresión; además, utilizan la reevaluación cognitiva como estrategia regulación emocional. Estas características dan lugar a intervenciones psicosociales de grupo en su hospital

Perfil psicosocial de un grupo de pacientes sobrevivientes de cáncer de mama

Resumen El propósito de este estudio fue evaluar las características psicosociales de un grupo de pacientes sobrevivientes de CaMa. Mediante un muestreo no probabilístico, por conveniencia, participaron diecisiete mujeres pertenecientes al Grupo de Sobrevivientes de Cáncer de Mama “Ave Fénix”, del CMN “20 de Noviembre”, ISSSTE. Se realizó una investigación no experimental, con diseño transversal exploratorio. Las pacientes respondieron el Cuestionario de Regulación Emocional, la Escala de Ansiedad y Depresión Hospitalaria y la Escala de Toronto de Alexitimia, durante una de las sesiones mensuales que sostiene el grupo. Los resultados sugieren que el grupo presenta un nivel alto de alexitimia, un nivel leve de ansiedad y poca depresión; además, utilizan la reevaluación cognitiva como estrategia regulación emocional. Estas características dan lugar a intervenciones psicosociales de grupo en su hospital.   Resumen El propósito de este estudio fue evaluar las características psicosociales de un grupo de pacientes sobrevivientes de CaMa. Mediante un muestreo no probabilístico, por conveniencia, participaron diecisiete mujeres pertenecientes al Grupo de Sobrevivientes de Cáncer de Mama “Ave Fénix”, del CMN “20 de Noviembre”, ISSSTE. Se realizó una investigación no experimental, con diseño transversal exploratorio. Las pacientes respondieron el Cuestionario de Regulación Emocional, la Escala de Ansiedad y Depresión Hospitalaria y la Escala de Toronto de Alexitimia, durante una de las sesiones mensuales que sostiene el grupo. Los resultados sugieren que el grupo presenta un nivel alto de alexitimia, un nivel leve de ansiedad y poca depresión; además, utilizan la reevaluación cognitiva como estrategia regulación emocional. Estas características dan lugar a intervenciones psicosociales de grupo en su hospital

Efectos diferenciales de la citoquina IL-6 después del estrés social agudo: resultados preliminares

Objetivo: evaluar el efecto diferencial del estrés social agudo sobre la interleucina 6 salival mediante la prueba conductual Trier Social Stress Test (tsst). Método: participaron diecisiete estudiantes universitarios, normotensos, a quienes se registró la presión arterial media en tres momentos: 10 minutos antes, pre y post tsst. También se recolectó una muestra de IL-6 salival pre-post tsst. Resultados: hubo un incremento en la presión arterial media sólo cuando se presentó el tsst (p0.05). El análisis de IL-6 reveló que 53 % de la muestra incrementó su concentración de IL-6 (p<0.001) mientras que 47 % de los participantes decrementó su nivel de IL-6 (p<0.01), existiendo una diferencia estadísticamente significativa post-tsst entre ambos subgrupos (p<0.05). Limitaciones: se recomienda establecer parámetros normativos de la IL-6 salival. Principales hallazgos: los datos preliminares que presentamos sugieren que el estrés social agudo incrementa la presión arterial, pero que este efecto induce una expresión diferencial de IL-6 en todos los participantes, en aquellos con una concentración baja de IL-6 se incrementa después del estrés agudo, mientras que aquellos con un nivel alto de IL-6 previo, la prueba tiende a disminuirla

The Fifteenth Data Release of the Sloan Digital Sky Surveys: First Release of MaNGA-derived Quantities, Data Visualization Tools, and Stellar Library

Twenty years have passed since first light for the Sloan Digital Sky Survey (SDSS). Here, we release data taken by the fourth phase of SDSS (SDSS-IV) across its first three years of operation (2014 July–2017 July). This is the third data release for SDSS-IV, and the 15th from SDSS (Data Release Fifteen; DR15). New data come from MaNGA—we release 4824 data cubes, as well as the first stellar spectra in the MaNGA Stellar Library (MaStar), the first set of survey-supported analysis products (e.g., stellar and gas kinematics, emission-line and other maps) from the MaNGA Data Analysis Pipeline, and a new data visualization and access tool we call "Marvin." The next data release, DR16, will include new data from both APOGEE-2 and eBOSS; those surveys release no new data here, but we document updates and corrections to their data processing pipelines. The release is cumulative; it also includes the most recent reductions and calibrations of all data taken by SDSS since first light. In this paper, we describe the location and format of the data and tools and cite technical references describing how it was obtained and processed. The SDSS website (www.sdss.org) has also been updated, providing links to data downloads, tutorials, and examples of data use. Although SDSS-IV will continue to collect astronomical data until 2020, and will be followed by SDSS-V (2020–2025), we end this paper by describing plans to ensure the sustainability of the SDSS data archive for many years beyond the collection of data

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

The Fifteenth Data Release of the Sloan Digital Sky Surveys: First Release of MaNGA-derived Quantities, Data Visualization Tools, and Stellar Library

Twenty years have passed since first light for the Sloan Digital Sky Survey (SDSS). Here, we release data taken by the fourth phase of SDSS (SDSS-IV) across its first three years of operation (2014 July–2017 July). This is the third data release for SDSS-IV, and the 15th from SDSS (Data Release Fifteen; DR15). New data come from MaNGA—we release 4824 data cubes, as well as the first stellar spectra in the MaNGA Stellar Library (MaStar), the first set of survey-supported analysis products (e.g., stellar and gas kinematics, emission-line and other maps) from the MaNGA Data Analysis Pipeline, and a new data visualization and access tool we call "Marvin." The next data release, DR16, will include new data from both APOGEE-2 and eBOSS; those surveys release no new data here, but we document updates and corrections to their data processing pipelines. The release is cumulative; it also includes the most recent reductions and calibrations of all data taken by SDSS since first light. In this paper, we describe the location and format of the data and tools and cite technical references describing how it was obtained and processed. The SDSS website (www.sdss.org) has also been updated, providing links to data downloads, tutorials, and examples of data use. Although SDSS-IV will continue to collect astronomical data until 2020, and will be followed by SDSS-V (2020–2025), we end this paper by describing plans to ensure the sustainability of the SDSS data archive for many years beyond the collection of data

Juxtaposing BTE and ATE – on the role of the European insurance industry in funding civil litigation

One of the ways in which legal services are financed, and indeed shaped, is through private insurance arrangement. Two contrasting types of legal expenses insurance contracts (LEI) seem to dominate in Europe: before the event (BTE) and after the event (ATE) legal expenses insurance. Notwithstanding institutional differences between different legal systems, BTE and ATE insurance arrangements may be instrumental if government policy is geared towards strengthening a market-oriented system of financing access to justice for individuals and business. At the same time, emphasizing the role of a private industry as a keeper of the gates to justice raises issues of accountability and transparency, not readily reconcilable with demands of competition. Moreover, multiple actors (clients, lawyers, courts, insurers) are involved, causing behavioural dynamics which are not easily predicted or influenced. Against this background, this paper looks into BTE and ATE arrangements by analysing the particularities of BTE and ATE arrangements currently available in some European jurisdictions and by painting a picture of their respective markets and legal contexts. This allows for some reflection on the performance of BTE and ATE providers as both financiers and keepers. Two issues emerge from the analysis that are worthy of some further reflection. Firstly, there is the problematic long-term sustainability of some ATE products. Secondly, the challenges faced by policymakers that would like to nudge consumers into voluntarily taking out BTE LEI

Search for stop and higgsino production using diphoton Higgs boson decays

Results are presented of a search for a "natural" supersymmetry scenario with gauge mediated symmetry breaking. It is assumed that only the supersymmetric partners of the top-quark (stop) and the Higgs boson (higgsino) are accessible. Events are examined in which there are two photons forming a Higgs boson candidate, and at least two b-quark jets. In 19.7 inverse femtobarns of proton-proton collision data at sqrt(s) = 8 TeV, recorded in the CMS experiment, no evidence of a signal is found and lower limits at the 95% confidence level are set, excluding the stop mass below 360 to 410 GeV, depending on the higgsino mass

Penilaian Kinerja Keuangan Koperasi di Kabupaten Pelalawan

This paper describe development and financial performance of cooperative in District Pelalawan among 2007 - 2008. Studies on primary and secondary cooperative in 12 sub-districts. Method in this stady use performance measuring of productivity, efficiency, growth, liquidity, and solvability of cooperative. Productivity of cooperative in Pelalawan was highly but efficiency still low. Profit and income were highly, even liquidity of cooperative very high, and solvability was good

Severe early onset preeclampsia: short and long term clinical, psychosocial and biochemical aspects

Preeclampsia is a pregnancy specific disorder commonly defined as de novo hypertension and proteinuria after 20 weeks gestational age. It occurs in approximately 3-5% of pregnancies and it is still a major cause of both foetal and maternal morbidity and mortality worldwide1. As extensive research has not yet elucidated the aetiology of preeclampsia, there are no rational preventive or therapeutic interventions available. The only rational treatment is delivery, which benefits the mother but is not in the interest of the foetus, if remote from term. Early onset preeclampsia (<32 weeks’ gestational age) occurs in less than 1% of pregnancies. It is, however often associated with maternal morbidity as the risk of progression to severe maternal disease is inversely related with gestational age at onset2. Resulting prematurity is therefore the main cause of neonatal mortality and morbidity in patients with severe preeclampsia3. Although the discussion is ongoing, perinatal survival is suggested to be increased in patients with preterm preeclampsia by expectant, non-interventional management. This temporising treatment option to lengthen pregnancy includes the use of antihypertensive medication to control hypertension, magnesium sulphate to prevent eclampsia and corticosteroids to enhance foetal lung maturity4. With optimal maternal haemodynamic status and reassuring foetal condition this results on average in an extension of 2 weeks. Prolongation of these pregnancies is a great challenge for clinicians to balance between potential maternal risks on one the eve hand and possible foetal benefits on the other. Clinical controversies regarding prolongation of preterm preeclamptic pregnancies still exist – also taking into account that preeclampsia is the leading cause of maternal mortality in the Netherlands5 - a debate which is even more pronounced in very preterm pregnancies with questionable foetal viability6-9. Do maternal risks of prolongation of these very early pregnancies outweigh the chances of neonatal survival? Counselling of women with very early onset preeclampsia not only comprises of knowledge of the outcome of those particular pregnancies, but also knowledge of outcomes of future pregnancies of these women is of major clinical importance. This thesis opens with a review of the literature on identifiable risk factors of preeclampsia